calcifediol profile

ID Source	ID
PubMed CID	5283731
CHEMBL ID	1040
CHEBI ID	17933
CHEBI ID	94743
SCHEMBL ID	3296
MeSH ID	M0003141

Synonym
CHEMBL1040
HY-32351
rayaldee
calcifediolum
(3s,5z,7e)-9,10-secocholesta-5,7,10-triene-3,25-diol
(3beta,5z,7e)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol
(3s,5z,7e)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol
(5z,7e)-(3s)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol
CHEBI:17933 ,
25(oh)d3
IDI1_033881
SPECTRUM5_001931
ro 8-8892
9,10-secocholesta-5,7,10(19)-triene-1,25-diol, (3.beta,.5z,7e)-
25-hydroxycholecalciferol
5,6-cis-25-hydroxyvitamin d3
(1s,3z)-3-[(2e)-2-[(1r,3as,7ar)-1-[(1r)-5-hydroxy-1,5-dimethyl-hexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylene-cyclohexanol
25-(oh)vitamin d3
cholecalciferol, 25-hydroxy-
3-{2-[1-(5-hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-ethylidene}-4-methylene-cyclohexanol
25-hydroxyvitamin d3
calcidiol ,
calcifediol anhydrous
(3s,5z,7e)-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol
C01561
25-hydroxycholecalciferol, >=98% (hplc)
DB00146
25-hydroxyvitamin d3 / 25-hydroxycholecalciferol / calcidiol
LMST03020246
NCGC00161326-01
calderol
u 32070 e
BSPBIO_001411
NCGC00161326-04
hidroferol
25-hydroxy vitamin d3
9,10-secocholesta-5,7,10(19)-triene-3,25-diol, (3beta,5z,7e)-
25-hydroxyvitamin d3 monohydrate, >=99.0% (hplc)
HMS1989G13
HMS2089L21
B91135EC-8937-4D8B-A533-CCD82F33C1B0
BML2-E02 ,
HMS1791G13
HMS1361G13
calcifediol [inn]
5,6-trans-25-hydroxycholescalciferol
didrogyl
delakmin
einecs 242-990-9
5,6-trans-9,10-seco-5,7,10(19)-cholestatrien-3beta,25-diol
calcifidiol
unii-t0wxw8f54e
25-hydroxycholescalciferol
hy-d
rovimix hy-d
t0wxw8f54e ,
(5z,7e)-9,10-seco-5,7,10(19)-cholestatrien-3beta,25-diol
calcifediolum [inn-latin]
dtxsid0022721 ,
64719-49-9
vitamin d, 25-hydroxy-
BCP9000472
AKOS015965097
BCPP000306
calcifediol [mi]
calcifediol,anhydrous
calcifediol,anhydrous [vandf]
calcifediol, anhydrous
CS-0800
S1469
ryaldee
gtpl6921
u-32070e
BRD-K77175907-001-01-5
DM100
SCHEMBL3296
AB01275461-01
(s,z)-3-((e)-2-((1r,3as,7ar)-1-((r)-6-hydroxy-6-methylheptan-2-yl)-7a-methylhexahydro-1h-inden-4(2h)-ylidene)ethylidene)-4-methylenecyclohexanol
JWUBBDSIWDLEOM-DTOXIADCSA-N
W-201718
(?r,1r,3as,4e,7ar)-4-[(2z)-2-[(5s)-5-hydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-?,?,?,7a-tetramethyl-1h-indene-1-pentanol
AC-31367
HMS3402G13
AB01275461_02
mfcd00867077
calcifediol, european pharmacopoeia (ep) reference standard
SR-05000001468-1
sr-05000001468
calcifediol, united states pharmacopeia (usp) reference standard
CHEBI:94743
25-hydroxy-cholecalciferol
9,10-secocholesta-5,7,10(19)-triene-3b,25-diol
(1s,3z)-3-{2-[(1r,3as,4e,7ar)-1-[(2r)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-octahydro-1h-inden-4-ylidene]ethylidene}-4-methylidenecyclohexan-1-ol
(3s,5z,14beta,17alpha)-9,10-secocholesta-5,7,10-triene-3,25-diol
Q139307
AMY2863
CCG-268657
(5z,7e)-9,10-secocholesta-5,7,10(19)-triene-3b,25-diol monohydrate
A923587
bdbm50521013
1h-indene-1-pentanol, octahydro-4-[(2z)-2-[(5s)-5-hydroxy-2-methylenecyclohexylidene]ethylidene]-.alpha.,.alpha.,.epsilon.,7a-tetramethyl-, (.epsilon.r,1r,3as,4e,7ar)-
EN300-7413489

Role	Description
bone density conservation agent	An agent that inhibits bone resorption and/or favor bone mineralization and bone regeneration. Used to heal bone fractures and to treat bone diseases such as osteopenia and osteoporosis.
nutraceutical	A product in capsule, tablet or liquid form that provide essential nutrients, such as a vitamin, an essential mineral, a protein, an herb, or similar nutritional substance.
metabolite	Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
human metabolite	Any mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
mouse metabolite	Any mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
hydroxycalciol
D3 vitamins	A vitamin D that is calciol or its hydroxylated metabolites calcidiol and calcitriol. Calciol (also known as vitamin D3) acts as a hormone precursor, being hydroxylated in the liver to calcidiol (25-hydroxyvitamin D3), which is then further hydroxylated in the kidney to give calcitriol (1,25-dihydroxyvitamin D3), the active hormone.
diol	A compound that contains two hydroxy groups, generally assumed to be, but not necessarily, alcoholic. Aliphatic diols are also called glycols.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Metabolism	1496	1108
Metabolism of lipids	500	463
Metabolism of steroids	111	135
Vitamin D (calciferol) metabolism	12	10
Biological oxidations	150	276
Phase I - Functionalization of compounds	69	175
Cytochrome P450 - arranged by substrate type	30	110
Vitamins	4	15
Disease	1278	231
Diseases of metabolism	69	121
Metabolic disorders of biological oxidation enzymes	6	47
Defective CYP27B1 causes VDDR1A	0	4
Vitamin D-sensitive calcium signaling in depression	2	13
Non-classical role of vitamin D	8	6
Vitamin D metabolism	1	9
Non-genomic actions of 1,25 dihydroxyvitamin D3	6	4
Vitamins A and D - action mechanisms	0	9

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
USP1 protein, partial	Homo sapiens (human)	Potency	17.7828	0.0316	37.5844	354.8130	AID504865
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	7.4269	0.0079	8.2332	1,122.0200	AID2546; AID2551
geminin	Homo sapiens (human)	Potency	10.5931	0.0046	11.3741	33.4983	AID624296
peripheral myelin protein 22	Rattus norvegicus (Norway rat)	Potency	17.2148	0.0056	12.3677	36.1254	AID624032; AID624044
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Sterol regulatory element-binding protein 1	Homo sapiens (human)	IC50 (µMol)	1.1760	1.1760	1.1760	1.1760	AID1765093
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Vitamin D3 receptor	Mus musculus (house mouse)	EC50 (µMol)	0.6000	0.0077	0.4019	0.9000	AID1585872
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial	Mus musculus (house mouse)	Km	0.4800	0.4800	0.4800	0.4800	AID1164487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
negative regulation of triglyceride metabolic process	Sterol regulatory element-binding protein 1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Sterol regulatory element-binding protein 1	Homo sapiens (human)
regulation of heart rate by chemical signal	Sterol regulatory element-binding protein 1	Homo sapiens (human)
lipid metabolic process	Sterol regulatory element-binding protein 1	Homo sapiens (human)
cholesterol biosynthetic process	Sterol regulatory element-binding protein 1	Homo sapiens (human)
response to nutrient	Sterol regulatory element-binding protein 1	Homo sapiens (human)
circadian rhythm	Sterol regulatory element-binding protein 1	Homo sapiens (human)
insulin receptor signaling pathway	Sterol regulatory element-binding protein 1	Homo sapiens (human)
lipid biosynthetic process	Sterol regulatory element-binding protein 1	Homo sapiens (human)
cellular response to starvation	Sterol regulatory element-binding protein 1	Homo sapiens (human)
response to xenobiotic stimulus	Sterol regulatory element-binding protein 1	Homo sapiens (human)
response to glucose	Sterol regulatory element-binding protein 1	Homo sapiens (human)
response to fructose	Sterol regulatory element-binding protein 1	Homo sapiens (human)
positive regulation of triglyceride biosynthetic process	Sterol regulatory element-binding protein 1	Homo sapiens (human)
regulation of lipid storage	Sterol regulatory element-binding protein 1	Homo sapiens (human)
regulation of fatty acid metabolic process	Sterol regulatory element-binding protein 1	Homo sapiens (human)
insulin secretion	Sterol regulatory element-binding protein 1	Homo sapiens (human)
lung development	Sterol regulatory element-binding protein 1	Homo sapiens (human)
intracellular receptor signaling pathway	Sterol regulatory element-binding protein 1	Homo sapiens (human)
regulation of protein stability	Sterol regulatory element-binding protein 1	Homo sapiens (human)
response to food	Sterol regulatory element-binding protein 1	Homo sapiens (human)
response to retinoic acid	Sterol regulatory element-binding protein 1	Homo sapiens (human)
response to progesterone	Sterol regulatory element-binding protein 1	Homo sapiens (human)
SREBP signaling pathway	Sterol regulatory element-binding protein 1	Homo sapiens (human)
response to glucagon	Sterol regulatory element-binding protein 1	Homo sapiens (human)
mRNA transcription by RNA polymerase II	Sterol regulatory element-binding protein 1	Homo sapiens (human)
fat cell differentiation	Sterol regulatory element-binding protein 1	Homo sapiens (human)
response to ethanol	Sterol regulatory element-binding protein 1	Homo sapiens (human)
positive regulation of cholesterol biosynthetic process	Sterol regulatory element-binding protein 1	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Sterol regulatory element-binding protein 1	Homo sapiens (human)
negative regulation of insulin secretion	Sterol regulatory element-binding protein 1	Homo sapiens (human)
response to cAMP	Sterol regulatory element-binding protein 1	Homo sapiens (human)
cellular response to fatty acid	Sterol regulatory element-binding protein 1	Homo sapiens (human)
regulation of mitophagy	Sterol regulatory element-binding protein 1	Homo sapiens (human)
positive regulation of miRNA transcription	Sterol regulatory element-binding protein 1	Homo sapiens (human)
regulation of protein targeting to mitochondrion	Sterol regulatory element-binding protein 1	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Sterol regulatory element-binding protein 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
RNA polymerase II transcription regulatory region sequence-specific DNA binding	Sterol regulatory element-binding protein 1	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Sterol regulatory element-binding protein 1	Homo sapiens (human)
transcription coregulator binding	Sterol regulatory element-binding protein 1	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Sterol regulatory element-binding protein 1	Homo sapiens (human)
DNA binding	Sterol regulatory element-binding protein 1	Homo sapiens (human)
chromatin binding	Sterol regulatory element-binding protein 1	Homo sapiens (human)
DNA-binding transcription factor activity	Sterol regulatory element-binding protein 1	Homo sapiens (human)
nuclear receptor activity	Sterol regulatory element-binding protein 1	Homo sapiens (human)
protein binding	Sterol regulatory element-binding protein 1	Homo sapiens (human)
protein kinase binding	Sterol regulatory element-binding protein 1	Homo sapiens (human)
sterol response element binding	Sterol regulatory element-binding protein 1	Homo sapiens (human)
protein dimerization activity	Sterol regulatory element-binding protein 1	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Sterol regulatory element-binding protein 1	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Sterol regulatory element-binding protein 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
Golgi membrane	Sterol regulatory element-binding protein 1	Homo sapiens (human)
nucleus	Sterol regulatory element-binding protein 1	Homo sapiens (human)
nuclear envelope	Sterol regulatory element-binding protein 1	Homo sapiens (human)
nucleoplasm	Sterol regulatory element-binding protein 1	Homo sapiens (human)
cytoplasm	Sterol regulatory element-binding protein 1	Homo sapiens (human)
endoplasmic reticulum membrane	Sterol regulatory element-binding protein 1	Homo sapiens (human)
cytosol	Sterol regulatory element-binding protein 1	Homo sapiens (human)
ER to Golgi transport vesicle membrane	Sterol regulatory element-binding protein 1	Homo sapiens (human)
chromatin	Sterol regulatory element-binding protein 1	Homo sapiens (human)
nucleus	Sterol regulatory element-binding protein 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (98)

Assay ID	Title	Year	Journal	Article
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID191113	Ability to mobilize Bone-Calcium transport, following the administration of compound in rats at a concentration of 50 pmol at 2 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID190599	Ability to stimulate intestinal-calcium transport by the administration of compound in rats at a concentration of 5000 pmol at 72 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID190592	Ability to stimulate intestinal-calcium transport by the administration of compound in rats at a concentration of 5000 pmol at 13 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID234898	Relative potency against calcium binding protein induction in duodenal organ culture at a concentration of 0.1 nM compared to 1,25-(OH)2-D3 in Male Albino rats	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID228114	Keq (k1/1-k) for the transformation of vitamin D to previtamin D	1994	Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15	14-epi stereoisomers of 25-hydroxy- and 1 alpha,25-dihydroxyvitamin D3: synthesis, isomerization to previtamins, and biological studies.
AID1585871	Activation of VDR in mouse ASZ001 cells assessed as change in Cyp24A1 mRNA expression at 1 uM after 48 hrs by q-PCR analysis relative to control	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Synthesis and evaluation of third generation vitamin D3 analogues as inhibitors of Hedgehog signaling.
AID191122	Ability to mobilize Bone-Calcium transport, following the administration of compound in rats at a concentration of 5 pmol at 2 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID191247	Ability to mobilize Bone-Calcium transport, following the administration of compound in rats at a concentration of 5 pmol at 4 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID190594	Ability to stimulate intestinal-calcium transport by the administration of compound in rats at a concentration of 5000 pmol at 2 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID1824244	Selectivity index, ratio of IC50 for Inhibition of hedgehog signalling in mouse VDR-KO MEF cells to IC50 for inhibition of hedgehog signalling in mouse ASZ001 cells	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Affinity-based protein profiling identifies vitamin D3 as a heat shock protein 70 antagonist that regulates hedgehog transduction in murine basal cell carcinoma.
AID25537	Compound was tested for the backward reaction of conversion of vitamin D to previtaminD	1994	Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15	14-epi stereoisomers of 25-hydroxy- and 1 alpha,25-dihydroxyvitamin D3: synthesis, isomerization to previtamins, and biological studies.
AID216929	Compound was evaluated for chick Vasoactive intestinal peptide receptor relative competitive induces (relative to alpha, 25-(OH2)-D3)	1994	Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15	14-epi stereoisomers of 25-hydroxy- and 1 alpha,25-dihydroxyvitamin D3: synthesis, isomerization to previtamins, and biological studies.
AID171533	Calcium binding protein induction in duodenal organ culture at a concentration of 0.1 nM in Male Albino rats	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID190613	Ability to stimulate intestinal-calcium transport by the administration of compound in rats at a concentration of 50 pmol at 47 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID191112	Ability to mobilize Bone-Calcium transport, following the administration of compound in rats at a concentration of 50 pmol at 24 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID190619	Ability to stimulate intestinal-calcium transport by the administration of compound in rats at a concentration of 5 pmol at 13 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID1824237	Activation of VDR in mouse C3H 10T1/2 cells assessed as upregulation of Cyp24A1 mRNA expression at 2.5 uM measured after 48 hrs by RT-PCR analysis relative to control	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Affinity-based protein profiling identifies vitamin D3 as a heat shock protein 70 antagonist that regulates hedgehog transduction in murine basal cell carcinoma.
AID191100	Ability to mobilize Bone-Calcium transport, following the administration of compound in rats at a concentration of 5000 pmol at 72 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID1164488	Ratio of kcat to Km for mouse CYP27B1 after 5 to 20 mins by HPLC analysis	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Synthesis and Biological Activity of 25-Hydroxy-2-methylene-vitamin D3 analogues monohydroxylated in the A-ring.
AID191114	Ability to mobilize Bone-Calcium transport, following the administration of compound in rats at a concentration of 50 pmol at 47 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID1824232	Inhibition of hedgehog signalling in mouse ASZ001 cells assessed as reduction in Gli1 mRNA expression measured after 48 hrs by RT-PCR analysis	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Affinity-based protein profiling identifies vitamin D3 as a heat shock protein 70 antagonist that regulates hedgehog transduction in murine basal cell carcinoma.
AID171536	Calcium binding protein induction in duodenal organ culture at a concentration of 1 nM in Male Albino rats	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID1765095	Inhibition of SREBP (unknown origin) expressed in CHO-K1 cells assessed as reduction in precursor SREBP protein level at 5 uM after 24 hrs by Western blotting analysis	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of a Vitamin D Receptor-Silent Vitamin D Derivative That Impairs Sterol Regulatory Element-Binding Protein In Vivo.
AID191096	Ability to mobilize Bone-Calcium transport, following the administration of compound in rats at a concentration of 5000 pmol at 47 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID1824243	Inhibition of hedgehog signalling in mouse VDR-KO MEF cells assessed as reduction in Gli1 mRNA expression measured after 48 hrs by RT-PCR analysis	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Affinity-based protein profiling identifies vitamin D3 as a heat shock protein 70 antagonist that regulates hedgehog transduction in murine basal cell carcinoma.
AID190741	Ability to stimulate intestinal-calcium transport by the administration of compound in rats at a concentration of 5 pmol at 2 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID191107	Ability to mobilize Bone-Calcium transport, following the administration of compound in rats at a concentration of 500 pmol at 4 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID1164475	Ratio of 1alpha,25-(OH)2D3 ED50 to compound ED50 for induction of human HL60 cell differentiation by nitro blue tetrazolium reduction assay	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Synthesis and Biological Activity of 25-Hydroxy-2-methylene-vitamin D3 analogues monohydroxylated in the A-ring.
AID1585868	Inhibition of Hedgehog signaling pathway in mouse ASZ001 cells assessed as reduction in oxysterol-induced Gli1 mRNA expression after 48 hrs by q-PCR analysis	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Synthesis and evaluation of third generation vitamin D3 analogues as inhibitors of Hedgehog signaling.
AID1585863	Inhibition of Hedgehog signaling pathway in mouse C3H10T1/2 cells assessed as reduction in oxysterol-induced Gli1 mRNA expression at 2.5 uM after 24 hrs by q-PCR analysis relative to oxysterol alone	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Synthesis and evaluation of third generation vitamin D3 analogues as inhibitors of Hedgehog signaling.
AID191098	Ability to mobilize Bone-Calcium transport, following the administration of compound in rats at a concentration of 5000 pmol at 4 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID1765097	Inhibition of FLAG-tagged SCAP (unknown origin) expressed in CHO-K1 cells assessed as reduction in SCAP protein level at 5 uM after 24 hrs by Western blotting analysis	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of a Vitamin D Receptor-Silent Vitamin D Derivative That Impairs Sterol Regulatory Element-Binding Protein In Vivo.
AID190597	Ability to stimulate intestinal-calcium transport by the administration of compound in rats at a concentration of 5000 pmol at 4 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID190602	Ability to stimulate intestinal-calcium transport by the administration of compound in rats at a concentration of 500 pmol at 24 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID1765085	Inhibition of SREBP (unknown origin) expressed in CHO-K1 cells at 5 uM by luciferase reporter assay	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of a Vitamin D Receptor-Silent Vitamin D Derivative That Impairs Sterol Regulatory Element-Binding Protein In Vivo.
AID1164476	Ratio of 1alpha,25-(OH)2D3 ED50 to compound ED50 for VDR-mediated 24-hydroxylase gene expression in rat ROS 17/2.8 cells after 16 hrs by luciferase reporter assay	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Synthesis and Biological Activity of 25-Hydroxy-2-methylene-vitamin D3 analogues monohydroxylated in the A-ring.
AID1765093	Inhibition of SREBP (unknown origin) expressed in CHO-K1 cells by luciferase reporter assay	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of a Vitamin D Receptor-Silent Vitamin D Derivative That Impairs Sterol Regulatory Element-Binding Protein In Vivo.
AID191123	Ability to mobilize Bone-Calcium transport, following the administration of compound in rats at a concentration of 5 pmol at 47 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID191109	Ability to mobilize Bone-Calcium transport, following the administration of compound in rats at a concentration of 500 pmol at 72 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID1765096	Inhibition of SREBP (unknown origin) expressed in CHO-K1 cells assessed as reduction in mature SREBP protein level at 5 uM after 24 hrs by Western blotting analysis	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of a Vitamin D Receptor-Silent Vitamin D Derivative That Impairs Sterol Regulatory Element-Binding Protein In Vivo.
AID216859	Bind to chick intestinal Vitamin D3 receptor for 1,25-(OH)2-D3	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID191093	Ability to mobilize Bone-Calcium transport, following the administration of compound in rats at a concentration of 5000 pmol at 13 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID190604	Ability to stimulate intestinal-calcium transport by the administration of compound in rats at a concentration of 500 pmol at 47 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID190615	Ability to stimulate intestinal-calcium transport by the administration of compound in rats at a concentration of 50 pmol at 4 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID191095	Ability to mobilize Bone-Calcium transport, following the administration of compound in rats at a concentration of 5000 pmol at 2 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID1824240	Binding affinity to recombinant human HSP70 assessed as dissociation constant incubated for 1 hrs by MTS assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Affinity-based protein profiling identifies vitamin D3 as a heat shock protein 70 antagonist that regulates hedgehog transduction in murine basal cell carcinoma.
AID190617	Ability to stimulate intestinal-calcium transport by the administration of compound in rats at a concentration of 50 pmol at 72 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID1164487	Activity of mouse CYP27B1 after 5 to 20 mins by HPLC analysis	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Synthesis and Biological Activity of 25-Hydroxy-2-methylene-vitamin D3 analogues monohydroxylated in the A-ring.
AID191103	Ability to mobilize Bone-Calcium transport, following the administration of compound in rats at a concentration of 500 pmol at 24 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID191105	Ability to mobilize Bone-Calcium transport, following the administration of compound in rats at a concentration of 500 pmol at 47 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID1585867	Activation of VDR in mouse C3H10T1/2 cells assessed as change in Cyp24A1 mRNA expression at 2.5 uM after 24 hrs by q-PCR analysis relative to control	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Synthesis and evaluation of third generation vitamin D3 analogues as inhibitors of Hedgehog signaling.
AID1164474	Ratio of 1alpha,25-(OH)2D3 Ki to compound Ki for full-length recombinant rat vitamin D receptor after 30 mins by liquid scintillation counting	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Synthesis and Biological Activity of 25-Hydroxy-2-methylene-vitamin D3 analogues monohydroxylated in the A-ring.
AID190611	Ability to stimulate intestinal-calcium transport by the administration of compound in rats at a concentration of 50 pmol at 24 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID25549	Compound was tested for rate constant for the forward reaction of isomerization of previtamin D to vitamin D	1994	Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15	14-epi stereoisomers of 25-hydroxy- and 1 alpha,25-dihydroxyvitamin D3: synthesis, isomerization to previtamins, and biological studies.
AID191104	Ability to mobilize Bone-Calcium transport, following the administration of compound in rats at a concentration of 500 pmol at 2 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID191118	Ability to mobilize Bone-Calcium transport, following the administration of compound in rats at a concentration of 50 pmol at 72 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID121189	In vitro bone-reabsorbing activity was examined in fetal mouse calvaria prelabeled with 45 Ca at 120 nM concentration, Ca release	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	Mechanism of the differentiating action of 25-hydroxyvitamin D3 endoperoxides in human myeloid leukemia cells (HL-60).
AID647370	Inhibition of Hedgehog signaling pathway in mouse C3H10T1/2 cells assessed as down regulation of Gli1 at 0.5 to 5 uM after 24 hrs by RT-PCR analysis	2012	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3	Evaluation of vitamin D3 A-ring analogues as Hedgehog pathway inhibitors.
AID190742	Ability to stimulate intestinal-calcium transport by the administration of compound in rats at a concentration of 5 pmol at 47 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID647368	Activation of VDR in mouse C3H10T1/2 cells assessed as up-regulation of CYP24A1 after 24 hrs by RT-PCR analysis relative to control	2012	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3	Evaluation of vitamin D3 A-ring analogues as Hedgehog pathway inhibitors.
AID191116	Ability to mobilize Bone-Calcium transport, following the administration of compound in rats at a concentration of 50 pmol at 4 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID1135798	Induction of intestinal calcium absorption in vitamin-D-deficient chicken assessed per 0.2 ml of plasma at 163 nmol, ip using 45Ca2+ and 40Ca2+ after 5 to 36 hrs	1978	Journal of medicinal chemistry, Oct, Volume: 21, Issue:10	Studies on vitamin D (calciferol) and its analogues. 15. 24-Nor-1alpha,25-dihydroxyvitamin D3 and 24-nor-25-hydroxy-5,6-trans-vitamin D3.
AID191249	Ability to mobilize Bone-Calcium transport, following the administration of compound in rats at a concentration of 5 pmol at 72 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID191094	Ability to mobilize Bone-Calcium transport, following the administration of compound in rats at a concentration of 5000 pmol at 24 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID190593	Ability to stimulate intestinal-calcium transport by the administration of compound in rats at a concentration of 5000 pmol at 24 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID191111	Ability to mobilize Bone-Calcium transport, following the administration of compound in rats at a concentration of 50 pmol at 13 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID190744	Ability to stimulate intestinal-calcium transport by the administration of compound in rats at a concentration of 5 pmol at 4 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID216847	Displacement of [3H]25-(OH)-D3 from rat plasma Vitamin D binding protein	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID55257	Evaluated for its binding affinity towards cytosol receptor in human myeloid leukemia cells (HL-60), by using 1-alpha,25-(OH)2D3 as radioligand	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	Syntheses and differentiating action of vitamin D endoperoxides. Singlet oxygen adducts of vitamin D derivatives in human myeloid leukemia cells (HL-60).
AID664921	Inhibition of colony formation of human HaCaT cells	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Design, synthesis, and biological action of 20R-hydroxyvitamin D3.
AID1824234	Activation of VDR in mouse ASZ001 cells assessed as upregulation of Cyp24A1 mRNA expression at 2.5 uM measured after 48 hrs by RT-PCR analysis relative to control	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Affinity-based protein profiling identifies vitamin D3 as a heat shock protein 70 antagonist that regulates hedgehog transduction in murine basal cell carcinoma.
AID191121	Ability to mobilize Bone-Calcium transport, following the administration of compound in rats at a concentration of 5 pmol at 24 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID121190	In vitro bone-reabsorbing activity was examined in fetal mouse calvaria prelabeled with 45 Ca at 12 nM concentration, Ca release	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	Mechanism of the differentiating action of 25-hydroxyvitamin D3 endoperoxides in human myeloid leukemia cells (HL-60).
AID1187831	Displacement of [3H]-1alpha,25-dihydroxyvitamin D3 from bovine thymus VDR measured after overnight incubation relative to 1alpha,25-dihydroxyvitamin D3	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	Synthesis and biological evaluation of 1α,25-dihydroxyvitamin D3 analogues with aromatic side chains attached at C-17.
AID1765102	Toxicity in ob/ob mouse assessed as sick at 10 mg/kg, ip administered 5 times per week for 4 weeks	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of a Vitamin D Receptor-Silent Vitamin D Derivative That Impairs Sterol Regulatory Element-Binding Protein In Vivo.
AID190595	Ability to stimulate intestinal-calcium transport by the administration of compound in rats at a concentration of 5000 pmol at 47 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID190601	Ability to stimulate intestinal-calcium transport by the administration of compound in rats at a concentration of 500 pmol at 13 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID190608	Ability to stimulate intestinal-calcium transport by the administration of compound in rats at a concentration of 500 pmol at 72 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID191102	Ability to mobilize Bone-Calcium transport, following the administration of compound in rats at a concentration of 500 pmol at 13 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID1765091	Effect on serum calcium level in mouse assessed as increase in calcium level at 10 mg/kg, ip administered once daily for 4 days by RT-PCR analysis	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of a Vitamin D Receptor-Silent Vitamin D Derivative That Impairs Sterol Regulatory Element-Binding Protein In Vivo.
AID1135797	Induction of bone calcium mobilization in vitamin-D-deficient chicken assessed per 100 ml of serum at 163 nmol, ip using 45Ca2+ and 40Ca2+ after 5 to 36 hrs	1978	Journal of medicinal chemistry, Oct, Volume: 21, Issue:10	Studies on vitamin D (calciferol) and its analogues. 15. 24-Nor-1alpha,25-dihydroxyvitamin D3 and 24-nor-25-hydroxy-5,6-trans-vitamin D3.
AID121188	In vitro bone-reabsorbing activity was examined in fetal mouse calvaria prelabeled with 45 Ca at 1.2 nM concentration, Ca release	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	Mechanism of the differentiating action of 25-hydroxyvitamin D3 endoperoxides in human myeloid leukemia cells (HL-60).
AID190620	Ability to stimulate intestinal-calcium transport by the administration of compound in rats at a concentration of 5 pmol at 24 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID191120	Ability to mobilize Bone-Calcium transport, following the administration of compound in rats at a concentration of 5 pmol at 13 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID1585872	Activation of VDR in mouse ASZ001 cells assessed as change in Cyp24A1 mRNA expression after 48 hrs by q-PCR analysis	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Synthesis and evaluation of third generation vitamin D3 analogues as inhibitors of Hedgehog signaling.
AID190612	Ability to stimulate intestinal-calcium transport by the administration of compound in rats at a concentration of 50 pmol at 2 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID190610	Ability to stimulate intestinal-calcium transport by the administration of compound in rats at a concentration of 50 pmol at 13 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID190746	Ability to stimulate intestinal-calcium transport by the administration of compound in rats at a concentration of 5 pmol at 72 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID1824236	Inhibition of hedgehog signalling in mouse C3H 10T1/2 cells assessed as reduction in Gli1 mRNA expression measured after 48 hrs by RT-PCR analysis	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Affinity-based protein profiling identifies vitamin D3 as a heat shock protein 70 antagonist that regulates hedgehog transduction in murine basal cell carcinoma.
AID171535	Calcium binding protein induction in duodenal organ culture at a concentration of 10 nM in Male Albino rats	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID82334	Evaluated for its ability to induce phagocytosis in human myeloid leukemia cells (HL-60)	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	Syntheses and differentiating action of vitamin D endoperoxides. Singlet oxygen adducts of vitamin D derivatives in human myeloid leukemia cells (HL-60).
AID190603	Ability to stimulate intestinal-calcium transport by the administration of compound in rats at a concentration of 500 pmol at 2 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID1585865	Inhibition of Hedgehog signaling pathway in mouse C3H10T1/2 cells assessed as reduction in oxysterol-induced Gli1 mRNA expression after 24 hrs by q-PCR analysis	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Synthesis and evaluation of third generation vitamin D3 analogues as inhibitors of Hedgehog signaling.
AID171532	Calcium binding protein induction in duodenal organ culture at a concentration of 0.01 nM in Male Albino rats	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID190606	Ability to stimulate intestinal-calcium transport by the administration of compound in rats at a concentration of 500 pmol at 4 hr.	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	3 (20.00)	18.7374
1990's	2 (13.33)	18.2507
2000's	0 (0.00)	29.6817
2010's	8 (53.33)	24.3611
2020's	2 (13.33)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	15 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (47)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
To Test the Effect of Calcifediol Hy.D Supplementation on Muscle Function and Bone Quality in Younger Postmenopausal Women With Osteopenia: a Double-blind Randomized Placebo-controlled Trial [NCT02527668]	Phase 2	150 participants (Anticipated)	Interventional	2015-09-30	Completed
Calcifediol in the Treatment of COVID 19. Modification of Therapeutic Response by Best Available Treatment or Other Treatment or Clinical Variables [NCT05819918]		728 participants (Actual)	Observational	2022-04-01	Completed
Activated Vitamin D for the Prevention and Treatment of Acute Kidney Injury (ACTIVATE-AKI) [NCT02962102]	Phase 2	150 participants (Actual)	Interventional	2017-04-03	Completed
Clearance of 25-hydroxyvitamin D in Chronic Kidney Disease [NCT02937350]	Phase 1	88 participants (Actual)	Interventional	2017-03-01	Completed
[NCT02517164]		300 participants (Anticipated)	Observational	2011-07-31	Recruiting
The Effect of Vitamin D Supplementation on Psoriasis Severity Measured by Psoriasis Area Severity Index (PASI) in Patients With Lower Range Serum 25-hydroxyvitamin D Levels [NCT03334136]		115 participants (Actual)	Interventional	2017-11-24	Completed
Vitamin D Level and Risk of Infections in Cirrhotic Patients: Does it Have a Role? [NCT03391245]		87 participants (Anticipated)	Observational	2017-08-01	Recruiting
The Effects of Vitamin D3 Versus 25OHD3 (HyD) on Serum Vitamin D Metabolites and Markers of Mineral Metabolism and Immune Function [NCT02091219]	Early Phase 1	35 participants (Actual)	Interventional	2014-06-30	Completed
Vitamin D Status in Inflammatory Bowel Disease [NCT03496246]		50 participants (Anticipated)	Interventional	2018-04-30	Enrolling by invitation
High-Dose Vitamin D3 Supplementation in the Treatment of Human Immune Deficiency Virus Patients: A Double-Blind Randomized Control Trial [NCT05306704]	Phase 3	95 participants (Actual)	Interventional	2019-02-15	Completed
Serum Levels of 25-Hydroxy Vitamin D in Patients With Moderate and Severe Erectile Dysfunction [NCT03867929]		130 participants (Actual)	Observational [Patient Registry]	2017-06-01	Completed
Assesment of Vit D3 Level in Cases of Unexplaind Pregnancy Loss in Assiut [NCT03327766]		100 participants (Anticipated)	Observational	2017-11-01	Not yet recruiting
Multicentric, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Effect of Vitamin D on Ventricular Remodeling in Patients With Acute Myocardial Infarction [NCT02548364]	Phase 3	109 participants (Actual)	Interventional	2015-10-31	Completed
An Open-Label, Repeated-Dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Oral CTAP101 Capsules, Immediate- Release (IR) Calcifediol, High-Dose Cholecalciferol, and Paricalcitol Plus Low-Dose Cholecalciferol in Patients With Secondary Hy [NCT03588884]	Phase 4	69 participants (Actual)	Interventional	2018-06-08	Completed
"Effect of Vitamin D Supplementation on the Allostatic Load and Chronic Stress Along Line of Control in Azad Jammu and Kashmir. Double Blind Randomized Placebo-controlled Trial" [NCT06101589]		120 participants (Anticipated)	Interventional	2023-12-15	Not yet recruiting
Clearance of 25-hydroxyvitamin D3 During Vitamin D3 Supplementation [NCT03576716]	Phase 1	19 participants (Actual)	Interventional	2018-06-01	Completed
Efficacy of Calcifediol Supplementation in Asthma Control in Asthmatic Patients With Vitamin D Deficiency (ACViD) [NCT02805907]	Phase 4	112 participants (Actual)	Interventional	2016-06-30	Completed
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Subjects With Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency [NCT01651000]	Phase 3	213 participants (Actual)	Interventional	2012-09-30	Completed
A Dietary Intervention Study Examining the Effect of Consumption of Vitamin D-enhanced Eggs on Winter-time Vitamin D Status in Adults [NCT02678364]		55 participants (Actual)	Interventional	2015-01-31	Completed
Monthly Vitamin D to Improve Vitamin D Status and Maintain Function in Pre-frail Older Individuals Living at Home [NCT01017354]	Phase 2	200 participants (Actual)	Interventional	2010-01-31	Completed
Prevention and Treatment With Calcifediol of COVID-19 Coronavirus-induced Acute Respiratory Syndrome (SARS) [NCT04366908]	Phase 2	517 participants (Actual)	Interventional	2020-05-07	Completed
Vitamin D Deficiency in the Elder Patients of General Departments and Its Treatment During the Hospitalization [NCT00640237]	Phase 3	300 participants (Anticipated)	Interventional	2008-03-31	Recruiting
The Effect of 25-hydroxyvitamin D Supplementation and a Structured Exercise Program on Exercise Capacity and Quality of Life in Dialysis Patients [NCT00798993]	Phase 4	19 participants (Actual)	Interventional	2009-01-31	Completed
Vitamin D Half-life in Pregnancy and Lactation [NCT02621827]		49 participants (Actual)	Interventional	2011-11-30	Completed
Comparison of the Bioefficacy of Oral 25-hydroxyvitamin D3 and Vitamin D3 Supplements on Vitamin D Status in Older Adults [NCT01398202]		56 participants (Actual)	Interventional	2011-01-31	Completed
The Impact of Vitamin K2 and Inactive Vitamin D Supplementation on Vascular Calcification in Pediatric Patients on Regular Hemodialysis [NCT04145492]	Phase 2/Phase 3	60 participants (Anticipated)	Interventional	2019-09-01	Recruiting
Effects of Vitamin D3 Supplementation in Asthma Control, Pulmonary Function and Th17 Inflammatory Biomarkers in Adolescents With Asthma, Obesity and Vitamin D Deficiency: a Randomized Clinical Trial [NCT05431920]		264 participants (Anticipated)	Interventional	2022-10-01	Recruiting
Clearance of 25-hydroxyvitamin D in Cystic Fibrosis [NCT03104855]	Phase 1	10 participants (Actual)	Interventional	2017-04-03	Completed
Fortification of Milk and Butter With Either vitaminD3 or 25(OH)D3: The Effect on Vitamin D Status and Cardiovascular Disease Risk Markers in Humans [NCT02535910]		18 participants (Anticipated)	Interventional	2015-08-31	Enrolling by invitation
Investigating the Effects of Hydroxyvitamin D3 Versus Vitamin D3 on Clinical, and Radiologic Progress and Th17/Tregs Balance in MS Patients: A Randomized, Clinical Trial- a Pilot Study [NCT05340985]	Phase 4	54 participants (Anticipated)	Interventional	2022-07-31	Not yet recruiting
Clinical Trial, Open, Parallel Groups , Value the Antiproteinuric Effects From Vitamin D Derivatives in Patient With Chronic Kidney Illness and the Lack of Vitamin D [NCT01442272]	Phase 4	174 participants (Anticipated)	Interventional	2012-01-31	Recruiting
Dose Finding Study in Physically Frail Elderly to Measure 25(OH) Vitamin D Levels After Supplementation With Hy.D Calcifediol 25 SD/S and Vitamin D3 [NCT01868945]	Phase 1	59 participants (Actual)	Interventional	2013-04-30	Completed
Effect of CTAP101 Capsules on Serum Calcium, Plasma Intact Parathyroid Hormone and Vitamin D Metabolites in Patients With Advanced Breast or Prostate Carcinomas With Metastases to Bone and Receiving Ongoing Therapy With Denosumab or Zoledronic Acid [NCT02274623]	Phase 1	33 participants (Actual)	Interventional	2014-12-31	Completed
Pilot Clinical Trial to Evaluate the Pharmacokinetics of Orally Administered 25-hydroxyvitamin D3 and Vitamin D3 in Healthy Adults and Adults With a History of Intestinal Malabsorption [NCT03401541]	Early Phase 1	16 participants (Actual)	Interventional	2018-10-01	Completed
Vitamin D Supplementation and HIV-related Complications in Children and Young Adults [NCT01523496]	Phase 2/Phase 3	190 participants (Actual)	Interventional	2011-12-31	Completed
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Subjects With Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency [NCT01704079]	Phase 3	216 participants (Actual)	Interventional	2012-11-30	Completed
Randomised, Double-blind, Double-dummy, Multicentre Trial to Evaluate the Efficacy and Safety of Three Different Weekly Dosages of Calcifediol Versus Placebo in Subjects With Either Vitamin D Deficiency or Insufficiency. [NCT04735926]	Phase 2/Phase 3	674 participants (Actual)	Interventional	2020-12-23	Completed
An Eight Week Double Blinded Randomized, Placebo-controlled Trial to Assess the Effect of Two Doses of 100,000 IU Vitamin D3 by Mouth on Select Genetic Responses in Overweight, Hypertensive African-Americans With Hypovitaminosis D [NCT02802449]		330 participants (Actual)	Interventional	2013-09-30	Completed
The Effect of Calcifediol (Hy.D 25 SD/S) and Vitamin D3 on Muscle Strength in a Frail Elderly Population: a Randomized, Double-blind, Placebo-controlled Trial. [NCT02349282]		78 participants (Actual)	Interventional	2014-12-31	Completed
The Response of Serum 25-hydroxyvitamin D to Different Doses of Calcifediol Hy.D Compared to Vitamin D3 Supplementation: A Randomized, Controlled, Double Blind, Long Term Pharmacokinetic Study [NCT02333682]		93 participants (Actual)	Interventional	2014-11-30	Completed
A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rayaldee (Calcifediol) Extended-release Capsules to Treat Symptomatic Patients Infected With SARS-CoV-2 (REsCue) [NCT04551911]	Phase 2	171 participants (Actual)	Interventional	2020-10-26	Completed
Preventive and Therapeutic Effects of Oral 25-hydroxyvitamin D3 on Coronavirus (COVID-19) in Adults [NCT04386850]	Phase 2/Phase 3	1,500 participants (Anticipated)	Interventional	2020-04-14	Recruiting
A Prospective Randomized Trial Comparing the Effects of 2 Vitamin D Supplementation Regimens in Elderly People After Hip Fracture Surgery [NCT03213886]	Phase 4	50 participants (Actual)	Interventional	2018-01-01	Completed
Serum Vitamin D Level Detection in Patients With Recurrent Pityriasis Versicolor [NCT05067699]		200 participants (Anticipated)	Observational	2021-09-01	Recruiting
Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Renal Transplantation. [NCT01939977]	Phase 4	148 participants (Actual)	Interventional	2014-01-31	Completed
A Long-term Safety and Efficacy Study of CTAP101 Capsules in Subjects With Stages 3 or 4 Chronic Kidney Disease, Secondary Hyperparathyroidism and Vitamin D Insufficiency (Extension of Study CTAP101-CL-3001 or CTAP101-CL-3002) [NCT02282813]	Phase 3	298 participants (Actual)	Interventional	2013-04-30	Completed
A Multi-Center, Randomized, Two-Cohort Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of CTAP101 (Calcifediol) Extended-Release Capsules to Treat Secondary Hyperparathyroidism in Subjects With Vitamin D Insufficiency [NCT03602261]	Phase 2	256 participants (Actual)	Interventional	2018-07-09	Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT01523496 (2) [back to overview]	Changes in Serum 25(OH)D3 Levels
NCT01523496 (2) [back to overview]	Changes in Vitamin D Binding Protein (VDBP)
NCT01651000 (4) [back to overview]	Number of Participants in the Intent to Treat Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline Values
NCT01651000 (4) [back to overview]	Number of Participants in the Per Protocol Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline Values
NCT01651000 (4) [back to overview]	Subjects in the Intent to Treat Population With Normal Serum Total 25-hydroxyvitamin D
NCT01651000 (4) [back to overview]	Subjects in the Per Protocol Population With Normal Serum Total 25-hydroxyvitamin D
NCT01704079 (4) [back to overview]	Subjects in the Per Protocol Population With Normal Serum Total 25-hydroxyvitamin D
NCT01704079 (4) [back to overview]	Number of Participants in the Intent to Treat Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline
NCT01704079 (4) [back to overview]	Number of Participants in the Per Protocol Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline
NCT01704079 (4) [back to overview]	Subjects in the Intent to Treat Population With Normal Serum Total 25-hydroxyvitamin D
NCT01939977 (8) [back to overview]	Evolution of Anti-HLA Antibodies (PRA) From Basal to Month 6 Post-transplantation.
NCT01939977 (8) [back to overview]	Frequency of Adverse Events or Serious Adverse Events That Occurs During the Study on Each Treatment Group.
NCT01939977 (8) [back to overview]	Change on Concentration of Bone Markers (Osteocalcin) at 6 Months After Transplantation on Each Treatment Group.
NCT01939977 (8) [back to overview]	Change on Concentration of Bone Markers (FGF-23) at 6 Months After Transplantation on Each Treatment Group
NCT01939977 (8) [back to overview]	Change on Concentration of Bone Markers (Alkaline Phosphatase) at 6 Months After Transplantation on Each Treatment Group.
NCT01939977 (8) [back to overview]	Change on iPTH Serum Concentration. Intention to Treat Analysis.
NCT01939977 (8) [back to overview]	Percentage of Patients on Each Stage of Renal Function on Months 1, 3 and 6 Post Transplantation.
NCT01939977 (8) [back to overview]	Percentage of Patients With Microalbuminuria on Months 1, 3 and 6 Post Transplantation.
NCT02282813 (4) [back to overview]	Number of Participants in the Per Protocol Population With NormalSerum 25-hydroxyvitamin D at End of Treatment (EOT)
NCT02282813 (4) [back to overview]	Number of Participants in the Intent to Treat Population With a Mean Reduction in Plasma Intact Parathyroid Hormone (iPTH) of >/= 30% From Baseline Values at End of Treatment (EOT)
NCT02282813 (4) [back to overview]	Number of Participants in the Intent to Treat Population With Normal Serum 25-hydroxyvitamin D at End of Treatment (EOT)
NCT02282813 (4) [back to overview]	Number of Participants in the Per Protocol Population With Mean Reduction in Plasma Intact Parathyroid Hormone (iPTH) of >/= 30% From Baseline Values at End of Treatment (EOT)
NCT02802449 (6) [back to overview]	Vitamin D3 Level
NCT02802449 (6) [back to overview]	Oxidative Stress Markers: Isoprostane
NCT02802449 (6) [back to overview]	Oxidative Stress Markers: Homocysteine
NCT02802449 (6) [back to overview]	Oxidative Stress Markers: Cysteine
NCT02802449 (6) [back to overview]	Oxidative Stress Markers: GSH
NCT02802449 (6) [back to overview]	Plasma PTH Level
NCT02805907 (3) [back to overview]	Quality of Life Measured With Mini-AQLQ (Asthma Quality of Life Questionnaire)
NCT02805907 (3) [back to overview]	Number of Asthma Exacerbations
NCT02805907 (3) [back to overview]	Asthma Control Measured With Asthma Control Test (ACT)
NCT02937350 (9) [back to overview]	Terminal Half-life of D6-25(OH)D3
NCT02937350 (9) [back to overview]	Change in the Serum Concentration of Calcium
NCT02937350 (9) [back to overview]	Change in the Serum Concentration of AST
NCT02937350 (9) [back to overview]	AUC of D6-25(OH)D3
NCT02937350 (9) [back to overview]	Metabolic Formation Clearance of D6-25(OH)D3 Metabolites.
NCT02937350 (9) [back to overview]	Metabolic Clearance of D6-25(OH)D3
NCT02937350 (9) [back to overview]	Change in the Serum Concentration of Creatinine
NCT02937350 (9) [back to overview]	Volume of Distribution of D6-25(OH)D3
NCT02937350 (9) [back to overview]	Change in the Serum Concentration of ALT
NCT02962102 (7) [back to overview]	28-day Mortality
NCT02962102 (7) [back to overview]	Death Within 7 Days
NCT02962102 (7) [back to overview]	Number of Participants Who Received Renal Replacement Therapy Within 7 Days
NCT02962102 (7) [back to overview]	Number of Participants With New or Worsening Stage of AKI, Defined by KDIGO Guidelines
NCT02962102 (7) [back to overview]	Peak Serum Creatinine (mg/dl)
NCT02962102 (7) [back to overview]	Relative Average Change in Serum Creatinine From Day 0 to Days 1-7
NCT02962102 (7) [back to overview]	ICU- and Hospital-free Days
NCT03104855 (9) [back to overview]	Metabolic Clearance of D6-25(OH)D3
NCT03104855 (9) [back to overview]	Metabolic Formation Clearance of D6-25(OH)D3 Metabolites
NCT03104855 (9) [back to overview]	Serum Concentration of ALT
NCT03104855 (9) [back to overview]	Serum Concentration of AST
NCT03104855 (9) [back to overview]	Serum Concentration of Calcium
NCT03104855 (9) [back to overview]	Volume of Distribution of D6-25(OH)D3
NCT03104855 (9) [back to overview]	Serum Concentration of Creatinine
NCT03104855 (9) [back to overview]	Terminal Half-life of D6-25(OH)D3
NCT03104855 (9) [back to overview]	AUC of D6-25(OH)D3
NCT03576716 (9) [back to overview]	Change in the Serum Concentration of ALT
NCT03576716 (9) [back to overview]	Change in Terminal Half-life of D6-25(OH)D3
NCT03576716 (9) [back to overview]	Change in Metabolic Clearance of D6-25(OH)D3
NCT03576716 (9) [back to overview]	Change in AUC of D6-25(OH)D3
NCT03576716 (9) [back to overview]	Changes in Metabolic Formation Clearance of D6-25(OH)D3 Metabolites.
NCT03576716 (9) [back to overview]	Change in Volume of Distribution of D6-25(OH)D3
NCT03576716 (9) [back to overview]	Change in the Serum Concentration of Creatinine
NCT03576716 (9) [back to overview]	Change in the Serum Concentration of Calcium
NCT03576716 (9) [back to overview]	Change in the Serum Concentration of AST
NCT03588884 (1) [back to overview]	Incidence and Severity of Treatment-Emergent Adverse Events (TEAE) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

Changes in Serum 25(OH)D3 Levels

Evaluate the dose-related efficacy of correction of Vitamin D deficiency for 25(OH)D3 levels in a group of HIV-infected children and young adults and a matched healthy control group in a randomized controlled study of different dosing regimens of oral Vitamin D supplementation: control dose (18,000 IU per month) or supplemented dose (medium 60,000IU per month or high dose 120,000IU/month ) (NCT01523496)
Timeframe: 6 months

Intervention	ng/mL (Median)
HIV Positive on Vit D Control Dose	11
HIV Positive on Vit D Supplementation Dose	22
HIV Negative on Vitamin D Control Dose	7.5
HIV Negative on Vitamin D Supplementation Dose	25

Intervention	ng/mL (Median)
HIV + on Vitamin D Control Dose	3.9
HIV + on Vit D Supplementation Dose	-8.9
HIV Negative on Vit D Control Dose	-11.3
HIV Negative on Vit D Supplementation Dose	-11.7

Intervention	participants (Number)
Sugar Pill to CTAP101 30 μg Capsule	6
CTAP101 30 μg Capsules	46

Intervention	Participants (Count of Participants)
	Screening Luminex at transplant71956367				Screening Luminex at transplant71956366	Screening Luminex at month 671956366	Screening Luminex at month 671956367
	Positive class I	Positive class II	Positive class I and II	Negative
Calcifediol	0
Paricalcitol	3
Calcifediol	4
Paricalcitol	35
Calcifediol	37
Paricalcitol	1
Paricalcitol	6
Calcifediol	3
Calcifediol	1
Paricalcitol	32
Calcifediol	38

Intervention	Participants (Count of Participants)
	Patients with adverse event (AE)	Patients with possibly or probably related AE	Patients with serious adverse event (SAE)	Patients with possibly or probably related SAE	Patients with AE that leads to discontinuation	Patients with moderate-severe adverse event
Calcifediol	38	1	20	0	4	28
Paricalcitol	41	2	24	0	2	34

Intervention	Osteocalcin ng/ml (Mean)
	Baseline Osteocalcin	Month 6 Osteocalcin
Calcifediol	12.62	5.20
Paricalcitol	11.74	4.02

Intervention	pg/mL (Mean)
	Baseline FGF-23	Month 6 FGF-23
Calcifediol	1359.56	289.14
Paricalcitol	2039.13	1937.30

Intervention	ug/L (Mean)
	Baseline alkaline phosphatase	Month 6 alkaline phosphatase
Calcifediol	14.50	11.79
Paricalcitol	13.85	11.68

Intervention	iPTH pg/ml (Mean)
	iPTH at month 6	iPTH at baseline
Calcifediol	101.27	315.47
Paricalcitol	75.63	338.48

Intervention	Participants (Count of Participants)
	Renal function at month 171956366						Renal function at month 171956367	Renal function at month 371956367	Renal function at month 371956366	Renal function at month 671956367	Renal function at month 671956366
	eGFR 30-59	eGFR 15-29	eGFR<15	N missing	eGFR >=90	eGFR 60-89
Calcifediol	4
Calcifediol	5
Paricalcitol	29
Calcifediol	27
Calcifediol	9
Paricalcitol	3
Calcifediol	1
Calcifediol	2
Calcifediol	10
Paricalcitol	26
Paricalcitol	8
Calcifediol	8
Calcifediol	0
Paricalcitol	6
Paricalcitol	1
Calcifediol	3
Paricalcitol	24
Calcifediol	25
Paricalcitol	9
Paricalcitol	2
Paricalcitol	5

Intervention	Participants (Count of Participants)
	Microalbuminuria month 171956367			Microalbuminuria month 171956366	Microalbuminuria month 371956366	Microalbuminuria month 371956367	MIcroalbuminuria month 671956366	MIcroalbuminuria month 671956367
	N missing	Normal (UACR<30 mg/g)	UACR 30-300 mg/g
Paricalcitol	18
Calcifediol	16
Calcifediol	1
Paricalcitol	25
Calcifediol	30
Paricalcitol	13
Calcifediol	12
Paricalcitol	3
Calcifediol	0
Paricalcitol	30
Calcifediol	35
Paricalcitol	16
Calcifediol	14
Paricalcitol	1
Paricalcitol	29
Calcifediol	33

Intervention	participants (Number)
CTAP101 Capsules (Not Randomized; 6 Mos Treatment)	86
CTAP101 Capsules (Not Randomized; 12 Mos Treatment)	120
CTAP101 Caps 2 x 30 mcg Daily for 12 wk+Adjunctive	37

Intervention	participants (Number)
CTAP101 Capsules (Not Randomized; 6 Mos Treatment)	34
CTAP101 Capsules (Not Randomized; 12 Mos Treatment)	66
CTAP101 Caps 2 x 30 mcg Daily for 12 wk+Adjunctive	30

Intervention	participants (Number)
CTAP101 Capsules (Not Randomized; 6 Mos Treatment)	87
CTAP101 Capsules (Not Randomized; 12 Mos Treatment)	124
CTAP101 Caps 2 x 30 mcg Daily for 12 wk+Adjunctive	38

Intervention	participants (Number)
CTAP101 Capsules (Not Randomized; 6 Mos Treatment)	34
CTAP101 Capsules (Not Randomized; 12 Mos Treatment)	64
CTAP101 Caps 2 x 30 mcg Daily for 12 wk+Adjunctive	29

Intervention	ng/ml (Mean)
	Baseline	Week 6
25 Hydroxy-Vitamin D3 or [25 (OH) D3]	16.55	32.73
Placebo	17.02	16.64

Intervention	pg/ml (Mean)
	Isoprostane (Baseline)	Isoprostane (Week 6)
25 Hydroxy-Vitamin D3 or [25 (OH) D3]	11914.9	9979.7
Placebo	8298.6	687.1

Intervention	umol/L (Mean)
	Homocysteine (Baseline)	Homocysteine (Week 6)
25 Hydroxy-Vitamin D3 or [25 (OH) D3]	11.9	11.8
Placebo	11.5	11.0

Intervention	umol/L (Mean)
	Cysteine (Baseline)	Cysteine (Week 6)
25 Hydroxy-Vitamin D3 or [25 (OH) D3]	252.4	241.2
Placebo	253.5	249.0

Intervention	umol/L (Mean)
	GSH (Baseline)	GSH (Week 6)
25 Hydroxy-Vitamin D3 or [25 (OH) D3]	4.1	3.5
Placebo	4.1	3.6

Intervention	Days (Median)
	ICU-free days	Hospital-free days
Calcifediol	20	5
Calcitriol	16	4
Placebo	11	0

Intervention	number of TEAE count (Number)
	Grade 1 Mild	Grade 2 Moderate	Grade 3 Severe	Grade Potentially Life Threatening	Grade 5 Fatal
Cholecalciferol	13	8	0	0	0
CTAP101	39	1	2	0	0
Immediate-release (IR) Calcifediol	12	3	3	0	0
Paricalcitol	10	5	1	0	0

Substance	Relationship Strength	Studies	Classes	Roles
cyclopamine [no description available]	2.07	1	piperidines	glioma-associated oncogene inhibitor
calcitriol dihydroxy-vitamin D3: as a major in vitro metabolite of 1alpha,25-dihydroxyvitamin D3, produced in primary cultures of neonatal human keratinocytes	3.72	10	D3 vitamins; hydroxycalciol; triol	antineoplastic agent; antipsoriatic; bone density conservation agent; calcium channel agonist; calcium channel modulator; hormone; human metabolite; immunomodulator; metabolite; mouse metabolite; nutraceutical
cholecalciferol Cholecalciferol: Derivative of 7-dehydroxycholesterol formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. It differs from ERGOCALCIFEROL in having a single bond between C22 and C23 and lacking a methyl group at C24.. calciol : A hydroxy seco-steroid that is (5Z,7E)-9,10-secocholesta-5,7,10(19)-triene in which the pro-S hydrogen at position 3 has been replaced by a hydroxy group. It is the inactive form of vitamin D3, being hydroxylated in the liver to calcidiol (25-hydroxyvitamin D3), which is then further hydroxylated in the kidney to give calcitriol (1,25-dihydroxyvitamin D3), the active hormone.	3.26	6	D3 vitamins; hydroxy seco-steroid; seco-cholestane; secondary alcohol; steroid hormone	geroprotector; human metabolite
mkt 077 MKT 077: structure given in first source	2.41	1
lg190178 [no description available]	2.69	2
gdc 0449 HhAntag691: inhibits the hedgehog pathway and ABC transporters; has antineoplastic activity	2.21	1	benzamides; monochlorobenzenes; pyridines; sulfone	antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist; teratogenic agent

Condition	Relationship Strength	Studies
Rachitis [description not available]	1.95	1
Granulocytic Leukemia [description not available]	2.37	2
Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.	2.37	2
Bone Loss, Osteoclastic [description not available]	1.96	1
Encephalitis, Polio [description not available]	2.06	1
Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)	2.06	1
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	2.31	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.31	1
Liver Steatosis [description not available]	2.31	1
Fatty Liver Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.	2.31	1
Carcinoma, Basal Cell, Pigmented [description not available]	2.41	1
Carcinoma, Basal Cell A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)	2.41	1

calcifediol

Cross-References

Synonyms (102)

Roles (5)

Drug Classes (3)

Pathways (17)

Protein Targets (7)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (37)

Molecular Functions (14)

Ceullar Components (9)

Bioassays (98)

Research

Studies (15)

Study Types

Clinical Trials (47)

Trial Overview

Trial Outcomes

Changes in Serum 25(OH)D3 Levels

Changes in Vitamin D Binding Protein (VDBP)

Number of Participants in the Intent to Treat Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline Values

Number of Participants in the Per Protocol Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline Values

Subjects in the Intent to Treat Population With Normal Serum Total 25-hydroxyvitamin D

Subjects in the Per Protocol Population With Normal Serum Total 25-hydroxyvitamin D

Subjects in the Per Protocol Population With Normal Serum Total 25-hydroxyvitamin D

Number of Participants in the Intent to Treat Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline

Number of Participants in the Per Protocol Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline

Subjects in the Intent to Treat Population With Normal Serum Total 25-hydroxyvitamin D

Evolution of Anti-HLA Antibodies (PRA) From Basal to Month 6 Post-transplantation.

Frequency of Adverse Events or Serious Adverse Events That Occurs During the Study on Each Treatment Group.

Change on Concentration of Bone Markers (Osteocalcin) at 6 Months After Transplantation on Each Treatment Group.

Change on Concentration of Bone Markers (FGF-23) at 6 Months After Transplantation on Each Treatment Group

Change on Concentration of Bone Markers (Alkaline Phosphatase) at 6 Months After Transplantation on Each Treatment Group.

Change on iPTH Serum Concentration. Intention to Treat Analysis.

Percentage of Patients on Each Stage of Renal Function on Months 1, 3 and 6 Post Transplantation.

Percentage of Patients With Microalbuminuria on Months 1, 3 and 6 Post Transplantation.

Number of Participants in the Per Protocol Population With NormalSerum 25-hydroxyvitamin D at End of Treatment (EOT)

Number of Participants in the Intent to Treat Population With a Mean Reduction in Plasma Intact Parathyroid Hormone (iPTH) of >/= 30% From Baseline Values at End of Treatment (EOT)

Number of Participants in the Intent to Treat Population With Normal Serum 25-hydroxyvitamin D at End of Treatment (EOT)

Number of Participants in the Per Protocol Population With Mean Reduction in Plasma Intact Parathyroid Hormone (iPTH) of >/= 30% From Baseline Values at End of Treatment (EOT)

Vitamin D3 Level

Oxidative Stress Markers: Isoprostane

Oxidative Stress Markers: Homocysteine

Oxidative Stress Markers: Cysteine

Oxidative Stress Markers: GSH

Plasma PTH Level

Quality of Life Measured With Mini-AQLQ (Asthma Quality of Life Questionnaire)

Number of Asthma Exacerbations

Asthma Control Measured With Asthma Control Test (ACT)

Terminal Half-life of D6-25(OH)D3

Change in the Serum Concentration of Calcium

Change in the Serum Concentration of AST

AUC of D6-25(OH)D3

Metabolic Formation Clearance of D6-25(OH)D3 Metabolites.

Metabolic Clearance of D6-25(OH)D3

Change in the Serum Concentration of Creatinine

Volume of Distribution of D6-25(OH)D3

Change in the Serum Concentration of ALT

28-day Mortality

Death Within 7 Days

Number of Participants Who Received Renal Replacement Therapy Within 7 Days

Number of Participants With New or Worsening Stage of AKI, Defined by KDIGO Guidelines

Peak Serum Creatinine (mg/dl)

Relative Average Change in Serum Creatinine From Day 0 to Days 1-7

ICU- and Hospital-free Days

Metabolic Clearance of D6-25(OH)D3

Metabolic Formation Clearance of D6-25(OH)D3 Metabolites

Serum Concentration of ALT

Serum Concentration of AST

Serum Concentration of Calcium

Volume of Distribution of D6-25(OH)D3

Serum Concentration of Creatinine

Terminal Half-life of D6-25(OH)D3

AUC of D6-25(OH)D3

Change in the Serum Concentration of ALT

Change in Terminal Half-life of D6-25(OH)D3

Change in Metabolic Clearance of D6-25(OH)D3